NAD+ vs NMN: Injectable Coenzyme or Oral Precursor?

NAD+ (nicotinamide adenine dinucleotide) and NMN (nicotinamide mononucleotide) are constantly compared because they sit one enzymatic step apart on the same salvage pathway. NMN is the immediate precursor: the NMNAT enzymes convert NMN to NAD+ inside the cell. The practical question is not which molecule matters (NAD+ is the one that does the work) but which delivery route actually raises intracellular NAD+ in a human being.

The Core Difference: Molecule Size and Route

NAD+ is a dinucleotide with a molecular weight of roughly 663 g/mol. It is large, charged, and does not cross the intestinal wall or the cell membrane intact in meaningful quantities. Swallowed NAD+ is largely broken down in the gut into nicotinamide and nicotinamide riboside before absorption, which is why NAD+ protocols use subcutaneous injection or IV infusion rather than capsules.

NMN is a mononucleotide at roughly 334 g/mol, about half the size. It survives oral dosing far better, and rodent work identified a dedicated small intestine transporter (Slc12a8) that takes up NMN directly. That is the entire argument for oral NMN: it is small enough to get in, and one enzyme away from the target.

Bioavailability: What the Human Data Shows

Human evidence is stronger for the oral precursors than for injectable NAD+. A 2020 Endocrine Journal study gave healthy men single oral NMN doses of 100, 250, and 500 mg and found the compound was safely metabolized without meaningful adverse effects, with downstream metabolites rising in plasma. A 2021 Science study dosed prediabetic women with 250 mg oral NMN daily for 10 weeks and reported improved skeletal muscle insulin sensitivity.

For the closely related precursor nicotinamide riboside, a 2018 Nature Communications trial in healthy middle-aged and older adults showed that 1000 mg per day elevated whole blood NAD+ by roughly 60 percent over six weeks, which is the clearest human proof that an oral precursor moves the endpoint you care about.

Injectable NAD+ has far less controlled human pharmacokinetic data. The rationale is mechanical rather than trial-based: bypassing the gut avoids first-pass degradation entirely. Subcutaneous and IV protocols are widely used in practice, but you should treat the specific dose numbers below as practice-derived rather than trial-validated.

Typical Dosing Compared

• Subcutaneous NAD+: 50 to 100 mg per day, often 5 days on and 2 days off. Reconstituted at 100 mg/mL, a 50 mg dose is 0.5 mL (50 units on a U100 syringe).
• IV NAD+: 250 to 750 mg per session, infused over 2 to 4 hours, typically 1 to 2 sessions per week rather than daily.
• Oral NMN: 250 to 1000 mg per day, taken in the morning on an empty stomach. Most human trials cluster at 250 to 500 mg.
• Oral NR (the common alternative precursor): 300 to 1000 mg per day, with 1000 mg being the dose used in the 60 percent NAD+ elevation trial.

Note the scale difference. Injectable NAD+ at 50 mg and oral NMN at 500 mg are not comparable on milligrams, because the oral route pays a large absorption and first-pass tax. Comparing the two by dose size alone is the most common mistake people make here.

Side Effects and Tolerability

Subcutaneous NAD+ is acidic in solution and frequently stings at the injection site, sometimes with redness lasting several hours. Rotating sites and injecting slowly over 20 to 30 seconds both help. Some users buffer the discomfort by splitting a 100 mg dose into two 50 mg injections at separate sites.

Oral NMN is generally well tolerated at the doses studied, with occasional reports of nausea, headache, or difficulty sleeping when taken late in the day. Because NAD+ metabolism is tied to circadian signaling, morning dosing is the standard recommendation for both routes.

Cost, Regulation, and Practical Access

Oral NMN is cheaper per day and needs no needles, no bacteriostatic water, and no refrigeration of a reconstituted vial. Its regulatory status in the United States is unsettled: in late 2022 the FDA took the position that NMN is excluded from the dietary supplement definition because it had been investigated as a new drug, which has affected retail availability without removing it from the market entirely.

Injectable NAD+ costs more per day and adds handling requirements. A 500 mg vial reconstituted with 5 mL of bacteriostatic water yields 100 mg/mL and gives you 10 doses at 50 mg. That vial must be refrigerated at 2 to 8 degrees Celsius and used within roughly 28 days, so vial sizing should match your actual dosing frequency.

If you are running injectable NAD+, use the NAD+ calculator to convert your vial size and BAC water volume into exact syringe units, or the general peptide calculator for any custom concentration.

Which One Should You Use?

1. If you want the strongest human evidence and the lowest friction, oral NMN or NR at 250 to 1000 mg daily is the defensible starting point.
2. If oral precursors have not produced a subjective effect after 8 to 12 weeks, subcutaneous NAD+ at 50 to 100 mg is the usual next step because it removes the absorption variable.
3. If you want a loading approach, IV NAD+ at 250 to 500 mg weekly for 4 weeks followed by oral NMN maintenance is a common pattern, though it is practice-derived rather than trial-supported.
4. Running both simultaneously is redundant on paper: they feed the same pool. If you stack them, drop the total of each rather than adding a full dose of one to a full dose of the other.